Clover Health (CLOV) reported its second consecutive profitable quarter with $478M in revenue and $17M adjusted EBITDA, beating expectations for the fifth straight quarter. Medicare Advantage ...
WILMINGTON, Del., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Financial Officer, ...
Clover delivers market-leading Medicare Advantage growth, establishing a strong path to achieve its first-ever full year GAAP Net Income profitability in 2026. Disciplined, core-market growth, strong ...
Clover Health Investments is now a contrarian buy, with the market underestimating its path to profitability in 2026. See why I rate the CLOV stock a Buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results